Effect of a novel antineoplastic drug olipifat on antitumor immunity in mice.

Abstract

Olipifat is an antineoplastic drug containing pyrophosphate and a product of special lignin processing. Donor C57Bl/6J mice with syngeneic B16 melanoma received a single 5-day course of olipifat. Effect of olipifat on antitumor resistance was evaluated by local neutralization test [3]. In animals with rapid melanoma growth, splenic cells from intact donors stimulated tumor growth. Olipifat abolished this growth-stimulating effect of splenocytes. In animals with slow melanoma growth, splenocytes had no effect on the growth of melanoma or Lewis lung cancer. In this case, splenocytes from olipifat-treated donors completely arrested the growth of melanoma B16 and decelerated the growth of Lewis lung carcinoma.

• Authors: V M Bukhman, D A Bodyagin, E R Pereverzeva, I D Treshchalin, E V Isakova, S E Krivosheev, V V Reztsova, V A Filov
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 132 Issue 4 Pg. 993-5 (Oct 2001) ISSN: 0007-4888 [Print] United States
• PMID: 11782803 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• olipifat
• Lignin

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Lewis Lung
• Lignin (analogs & derivatives, therapeutic use)
• Lymph Nodes (drug effects)
• Lymphatic Metastasis
• Melanoma, Experimental
• Mice
• Mice, Inbred C57BL
• Spleen (drug effects)
• Thymus Gland (drug effects)
• Time Factors